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CASE REPORT 
Uncontrolled Self-Medication with Venlafaxine in a Patient  
with Major Depressive Disorder
Ji-Hye Song, Bum-Hee Yu, Dongsoo Lee, Se Chang Yoon and Hong Jin Jeon
 
Department of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Antidepressants are known to have no significant ability to cause addiction. However, a recent study showed many individuals with mood 
disorders self-medicated with antidepressants to relieve symptoms. We report here a male physician, diagnosed five years ago with major 
depressive disorder, with insomnia, anxiousness, and chest heaviness. He began self-medicating with 150 mg of venlafaxine daily, without 
any monitoring. During his most recent severe depressive episode, he was taking up to 1,500 mg of venlafaxine daily. Without this medicat-
ion, he experienced discontinuation syndrome, which included severe anxiety, chest heaviness, and breathing difficulty, and which he 
judged as indicating a more severely depressed state. He also experienced overdose symptoms, such as hypertension and tachycardia. He 
attempted suicide with drugs that he possessed. In conclusion, careful monitoring is needed when treating patients with venlafaxine, be-
cause its discontinuation syndrome is similar to symptoms of major depressive disorder, and suicidality may result from an overdose.
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INTRODUCTION
Most authorities do not regard antidepressants as causing 
dependency in patients with major depressive disorder, but 
some researchers have challenged this presumption.
1 The Na-
tional Epidemiologic Survey on Alcohol and Related Condi-
tions revealed that almost one-quarter of individuals with 
mood disorders used alcohol or self-medication, including an-
tidepressants, to relieve their symptoms.
2
Few studies have focused on self-medication and antide-
pressant abuse in patients with major depressive disorder. In 
this paper, we report a case of a male physician who abused 
venlafaxine without any monitoring. The antidepressant ven-
lafaxine inhibits the reuptake of both serotonin and norepi-
nephrine, with a 30-fold higher affinity for serotonin than for 
norepinephrine.
3 Venlafaxine has a short half-life of 3.5 hours,
4 
and it can produce discontinuation syndrome if the patient 
abruptly stops taking it.
The individual in question read this report before we sub-
mitted it. Moreover, we have received a signed informed con-
sent for publication from the subject of this case report. 
CASE
A male physician in his mid-40s presented to an emergen-
cy center with his first suicide attempt, which he had performed 
by inhaling some drugs, including venlafaxine. He had no his-
tory of alcohol or illicit drug abuse.
Five years ago, he had experienced his first depressive epi-
sode, with insomnia, anxiousness, and chest heaviness (Figure 
1). The heaviness had been in the epigastric area, sometimes 
lasted all day, and deepened under stress. He had checked him-
self into a hospital. While there, he was told there was noth-
ing wrong with his heart. He had then visited a psychiatrist, who 
prescribed venlafaxine. However, he had not visited the clinic 
again, instead prescribing 150 mg of extended-release venla-
faxine for himself thereafter, which produced a partial improve-
ment. However, he worsened again after marital conflicts and 
increased his venlafaxine dose to 300 mg. After he and his wife 
had a child, he improved, and he reduced his venlafaxine dos-
age to 150 mg.
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Two and one-half years ago, the patient had experienced a 
more serious depressive episode, despite continuously taking 
the self-prescribed venlafaxine. His depressive episode partial-
ly eased after three months. However, one and one-half years ago, 
the patient’s depression returned. He went back to the psychi-
atric clinic again, and his psychiatrist prescribed paroxetine 
and bupropion, which he took in addition to the self-prescrib-
ed venlafaxine. These had little effect on his mood, and he dis-
continued visiting the psychiatric clinic. 
He judged himself as being in a more severely depressed st-
ate, because his depressive mood did not improve even though 
he was taking his previous dose of venlafaxine. Then, he gradu-
ally increased the venlafaxine dose, up to 1,500 mg (75 mg× 
20 pills) per day. He took most of these pills before sleeping 
or when he felt anxiety or depressive symptoms.
When he discontinued the venlafaxine, he experienced dis-
continuation syndrome: neuropsychiatric symptoms, such as 
depressed mood, severe anxiety, irritability, and impulsiveness; 
gastrointestinal symptoms, such as nausea; neuromotor symp-
toms, such as tremors in both hands; neurosensory symptoms, 
such as vertigo, paresthesias, and unbearable chest heaviness 
and breathing difficulty, which were most severe when he got 
up in the morning; vasomotor symptoms, such as diaphoresis; 
and other neurologic symptoms, such as insomnia, anorexia, 
and asthenia, as Delgado
5 described.
He also experienced psychological dependence on venla-
faxine. He reported feeling intense fear without venlafaxine, 
and he kept a large amount of it in his own home, because he 
had experienced seriously depressed mood and discontinua-
tion syndrome without it. However, he never experienced an 
amphetamine-like high during his use.
Fifteen days prior to his visit to the emergency center, he at-
tempted suicide with drugs that he possessed, including venla-
faxine. Despite not receiving any emergency treatment at that 
time, he survived. He felt a lack of will to go on with everyday 
life or to treat himself, so he admitted himself to our ward for 
treatment.
On admission, he reported both discontinuation syndrome 
and overdose symptoms. He experienced severe anxiety and ag-
itation (Figure 2). He experienced poor sleep induction, and 
he awakened three times per sleep period, even after taking 
sleeping pills. He felt pain in the epigastric area. He also sh-
owed overdose symptoms, with a high blood pressure of 173/ 
124 mmHg, and he took 5 mg of amlodipine daily. His EKG 
was within normal ranges but showed tachycardia, with a 
heart rate of 110/min. His laboratory tests, including complete 
blood cell count, liver and thyroid function tests, urine test, and 
lipid profile, were also within normal ranges. His quantitative 
and simple waking EEGs gave no significant findings. We es-
timated his cognitive functions as normal.
The patient’s treatment consisted of a cessation of venla-
faxine and the following prescriptions: 1 mg of clonazepam 
and 100 mg of amisulpride, for his agitation and chest discom-
fort; 15 mg of mirtazapine and 25 mg of trazodone, for depres-
sive mood and insomnia; and 80 mg of ginkgo biloba, for tin-
nitus and dizziness. After admission, he recovered from the dis-
continuation syndrome, overdose symptoms, and depression 
(Figure 2). On the 24th day, we discharged the patient with a 
scheduled follow-up visit at the outpatient clinic. The patient 
began visiting the outpatient clinic regularly and ceased to take 
any self-prescribed medication.
DISCUSSION
This patient continuously prescribed venlafaxine for himself 
for 5 years. His uncontrollable self-medication lead to severe 
mood fluctuations and a suicide attempt during his last depres-
sive episode. The recommended venlafaxine dosage ranges from 
150 mg/day up to 375 mg/day in severely depressed patients,
6 
but this patient took up to 1,500 mg/day.
Self-medication of antidepressants without any monitoring 
is dangerous, because of the concomitant poor evaluation and 
management of the depression. Patients’ views about depres-
sive symptoms differ significantly from medical views, and dif-
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ferentiating “depression” from understandable reactions to ad-
versity is difficult for patients.
7 Antidepressants are also asso-
ciated with the potential risk of treatment-emergent mania, 
hypomania, or a mixture, according to evidence from the Na-
tional Institute of Mental Health Systematic Treatment En-
hancement Program for Bipolar Disorder.
8 
Discontinuation syndrome has been reported with nearly all 
antidepressants, but most commonly with venlafaxine and pa-
roxetine.
9,10 Delgado
5 reported patients who discontinued se-
rotonin reuptake inhibitor treatment tended to experience 
six kinds of somatic symptoms: neuropsychological, gastro-
intestinal, neuromotor, neurosensory, vasomotor, and other 
neurologic symptoms. The patients experienced all kinds of 
discontinuation symptoms, which are similar to symptoms of 
major depressive disorder. A previous study showed that an-
tidepressant discontinuation in depressed patients sometimes 
correlated with worsening depression and increased suicidality.
11
Venlafaxine overdose is associated with sedation, sinus ta-
chycardia, seizures, hypertension, hypotension, diaphoresis, 
and hyponatremia.
12 Our patient showed newly developed hy-
pertension and tachycardia. Researchers have observed a dose-
related increase in mean blood pressure with venlafaxine use, 
especially with doses of more than 300 mg daily.
13 Cardiac rhy-
thm disturbances, including an increase of QTc leading to 
atrial fibrillation, have also been reported.
12 Fatalities due to ov-
erdose of venlafaxine have also been reported.
12,14
Our patient experienced both discontinuation syndrome 
and venlafaxine overdose symptoms, along with symptoms 
of major depressive disorder. He could not help but continue 
his self-medication, in spite of the discontinuation syndrome. 
This patient did not visit any clinics until his suicide attempt, 
because he regarded his venlafaxine overdose and withdraw-
al symptoms as depressive symptoms. As a physician, he had 
confidence that he could treat his depression without any as-
sistance. Approximately 10% to 12% of physicians will develop 
a substance use disorder during their careers, a rate similar 
to, or exceeding, that of the general population in America.
15-17
Another explanation for venlafaxine abuse is its amphet-
amine-like effect with large dosages, which mimics amphet-
amine-like highs.
18 This might relate to venlafaxine’s action 
mechanism, which blocks not only serotonin but also norepi-
nephrine reuptake and weakly inhibits dopamine reuptake.
6 
However, our patient did not experience highs while taking 
venlafaxine.
In conclusion, venlafaxine discontinuation syndrome has 
symptoms similar to those of major depressive disorder, de-
pending on each patient’s experience, and an overdose may 
produce suicidality or a fatal outcome. Therefore, self-medi-
cation with venlafaxine should be avoided, and careful moni-
toring is needed when using it to treat patients with major de-
pressive disorder.
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